Eton Pharmaceuticals (ETON) closed at $52.18 on October 30, 2026, down 2.8% from the previous close, on volume of 322,851 shares (30-day average 534,254).
Data as of October 30, 2026.
30-Oct-2026
Investors pivot to safety as low-volatility stocks back in spotlight
Seeking Alpha News (Fri, 30-Oct 10:19 AM ET)
Eton Pharmaceuticals to Report Third Quarter 2026 Financial Results on Thursday, November 5, 2026
Globe Newswire (Thu, 29-Oct 6:50 AM ET)
Globe Newswire (Wed, 14-Oct 6:50 AM ET)
Eton Pharmaceuticals Announces U.S. Commercial Availability of IMPAVIDO (miltefosine) Capsules
Globe Newswire (Mon, 28-Sep 6:50 AM ET)
Eton Pharmaceuticals to Participate at 2026 Wells Fargo Healthcare Conference
Globe Newswire (Thu, 27-Aug 6:50 AM ET)
Record Revenue and Higher Guidance Highlight Eton Pharmaceuticals’ Standout Quarter
Market Chameleon (Fri, 14-Aug 6:30 AM ET)
Market Chameleon (Fri, 14-Aug 3:27 AM ET)
Eton Pharmaceuticals Reports Second Quarter 2026 Financial Results
Globe Newswire (Thu, 13-Aug 4:05 PM ET)
Globe Newswire (Wed, 5-Aug 6:50 AM ET)
Eton Pharmaceuticals to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026
Globe Newswire (Mon, 3-Aug 6:50 AM ET)
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has eight commercial rare disease products, INCRELEX, ALKINDI SPRINKLE, KHINDIVITM, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous and Nitisinone. It also has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjector.
Eton Pharmaceuticals trades on the NASDAQ stock market under the symbol ETON.
As of October 30, 2026, ETON stock price declined to $52.18 with 322,851 million shares trading.
ETON has a beta of -0.34, meaning it tends to be less sensitive to market movements. ETON has a correlation of 0.01 to the broad based SPY ETF.
ETON has a market cap of $1.49 billion. This is considered a Small Cap stock.
Last quarter Eton Pharmaceuticals reported $38 million in Revenue and $.43 earnings per share. This beat revenue expectation by $10 million and exceeded earnings estimates by $.25.
In the last 3 years, ETON traded as high as $66.37 and as low as $3.03.
The top ETF exchange traded funds that ETON belongs to (by Net Assets): VTI, IWM, VXF, IWO, FYC.
ETON has outperformed the market in the last year with a price return of +185.9% while the SPY ETF gained +12.3%. ETON has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +6.4% and +3.7%, respectively, while the SPY returned +2.1% and -1.0%, respectively.
ETON support price is $52.05 and resistance is $55.30 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ETON shares will trade within this expected range on the day.